ABCDEFGHIJKLMNOPQRSTUVWXYZ
1
Calendar Year (CY) 2023 Clinical Laboratory Fee Schedule (CLFS) Preliminary Payment Determinations1

This worksheet “A. Preliminary Determinations” of this Excel workbook contains all of the new CLFS codes and CMS preliminary payment determinations.

We welcome public comments on our preliminary determinations for the basis of payment. All comments must be submitted electronically by October 24, 2022 to the following CMS mailbox: CLFS_Annual_Public_Meeting@cms.hhs.gov, and final determinations will be announced in November. When submitting public comments, please refer to the specific code and its rationale so that we may best respond in the final payment determinations.

1CPT codes, descriptions and other data only are copyright 2021 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.
2
FACA Mtg. ItemALM Code List Item #Code #Code TypeCategoryLong Code DescriptorPanel RecommendationCMS 2022 Preliminary RecommendationRationale
3
17584XXXNEWChemistryThiopurine S-methyltransferase (TPMT)Crosswalk to 82657: 1
Gapfill: 11
Abstain: 0		Crosswalk to 82657CMS agrees with the minority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
4
23980220ReconsiderationChemistryHydroxychloroquineCrosswalk to 80204: 10
Crosswalk to 80299: 2
Gapfill: 0
Abstain 0		Crosswalk to 80299CMS agrees with the minority CDLT Panel recommendation to crosswalk the code and continues to believe a crosswalk to CPT 80299 is appropriate as both codes use similar methods.
5
34183529ReconsiderationChemistryInterleukin-6 (IL-6)Crosswalk to 83006: 9
Crosswalk to 83520: 3
Gapfill: 0
Abstain: 0		Crosswalk to 83520CMS agrees with the minority CDLT Panel recommendation to crosswalk the code and continues to believe a crosswalk to CPT 83520 is appropriate as both codes use similar methods.
6
4960X46UPLAChemistry
Hepatology (nonalcoholic fatty liver disease [NAFLD]), semiquantitative evaluation of 28 lipid markers by liquid chromatography with tandem mass spectrometry (LC-MS/MS), serum, reported as at-risk for nonalcoholic steatohepatitis (NASH) or not NASHGapfill: 12
Abstain: 0		GapfillCMS agrees with the majority recommendation of the CDLT Panel to gapfill this code so that the resources used in this code can be better estimated by a Medicare Administrative Contractor (MAC).
7
5980X48UPLAChemistryBeta amyloid, Aβ40 and Aβ42 by liquid chromatography with tandem mass spectrometry (LC-MS/MS), ratio, plasmaGapfill: 12
Abstain: 0		Crosswalk to 82542CMS disagrees with the Panel Recommendation and instead is recommending a crosswalk. The crosswalked code(s) appear to use similar methods and resource utilization.
8
6140298UPLAGenomic Sequencing Related Tests WHOLE GENOME Drug metabolism pharmacogenomics/pharmcogeneticsOncology (pan tumor), whole transcriptome sequencing of paired malignant and normal RNA specimens, fresh or formalin-fixed paraffin-embedded (FFPE) tissue, blood or bone marrow, comparative sequence analyses and expression level and chimeric transcript identification
Crosswalk to 0266U TIMES 1.5: 10
Gapfill: 2
Abstain: 0
Crosswalk to 0204UCMS disagrees with the Panel Recommendation and instead is recommending a crosswalk. The crosswalked code(s) appear to use similar methods and resource utilization.
9
7130297UPLAGenomic Sequencing Related Tests WHOLE GENOME Drug metabolism pharmacogenomics/pharmcogenetics Oncology (pan tumor), whole genome sequencing of paired malignant and normal DNA specimens, fresh or formalinfixed paraffin-embedded (FFPE) tissue, blood or bone marrow, comparative sequence analyses and variant identification

Crosswalk to 0265U TIMES 1.5: 10
Crosswalk to 0013U: 0
Crosswalk to 81425: 0
Gapfill: 2
Abstain: 0		Crosswalk to 81425CMS disagrees with the Panel Recommendation and instead is recommending a crosswalk. The crosswalked code(s) appear to use similar methods and resource utilization.
10
8150299UPLAGenomic Sequencing Related Tests WHOLE GENOME Drug metabolism pharmacogenomics/pharmcogeneticsts Oncology (pan tumor), whole genome optical genome mapping of paired malignant and normal DNA specimens, fresh frozen tissue, blood, or bone marrow, comparative structural variant identification

Crosswalk to 0264U TIMES 1.5: 10
Gapfill: 2
Abstain: 0
GapfillCMS agrees with the minority recommendation of the CDLT Panel to gapfill this code so that the resources used in this code can be better estimated by a Medicare Administrative Contractor (MAC).
11
9160300UPLAGenomic Sequencing Related Tests WHOLE GENOME Drug metabolism pharmacogenomics/pharmcogeneticsts Oncology (pan tumor), whole genome sequencing and optical genome mapping of paired malignant and normal DNA specimens, fresh tissue, blood, or bone marrow, comparative sequence analyses and variant identification

Crosswalk to 0267U TIMES 1.5: 10
Gapfill: 2
Abstain: 0

GapfillCMS agrees with the minority recommendation of the CDLT Panel to gapfill this code so that the resources used in this code can be better estimated by a Medicare Administrative Contractor (MAC).
12
10708X000NEWGenomic Sequencing Related Tests TARGETED Drug metabolism pharmacogenomics/pharmcogeneticsDrug metabolism (eg, pharmacogenomics) genomic sequence analysis panel, must include testing of at least 6 genes, including CYP2C19, CYP2D6, and CYP2D6 duplication/deletion analysisCrosswalk to 81225 + 0070U: 1
Crosswalk to 81435 + 81436: 0
Crosswalk to 81413 + 81414: 0
Gapfill: 11
Abstain: 0
Crosswalk to 0029UCMS disagrees with the Panel Recommendation and instead is recommending a crosswalk. The crosswalked code(s) appear to use similar methods and resource utilization.
13
11950X45UPLAGenomic Sequencing Related Tests TARGETED Drug metabolism pharmacogenomics/pharmcogeneticsDrug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 27 gene report, with variant analysis including reported phenotypes and impacted gene-drug interactionsGapfill: 12
Abstain: 0		Crosswalk to 0029UCMS disagrees with the Panel Recommendation and instead is recommending a crosswalk. The crosswalked code(s) appear to use similar methods and resource utilization.
14
12970X47UPLAGenomic Sequencing Related Tests TARGETED Drug metabolism pharmacogenomics/pharmcogeneticsPsychiatry (eg, depression, anxiety, attention deficit hyperactivity disorder [ADHD]), genomic analysis panel, variant analysis of 15 genes, including deletion/duplication analysis of CYP2D6Crosswalk to 0175U: 12
Gapfill: 0
Abstain: 0		Crosswalk 0175UCMS agrees with the majority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
15
13990X50UPLAGenomic Sequencing Related Tests TARGETED Drug metabolism pharmacogenomics/pharmcogeneticsDrug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 25 gene report, with variant analysis and reported phenotypesGapfill: 12
Abstain: 0		Crosswalk to 0029UCMS disagrees with the Panel Recommendation and instead is recommending a crosswalk. The crosswalked code(s) appear to use similar methods and resource utilization.
16
141000X51UPLAGenomic Sequencing Related Tests TARGETED Drug metabolism pharmacogenomics/pharmcogeneticsDrug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 16 gene report, with variant analysis and reported phenotypesCrosswalk to 0175U: 12
Gapfill: 0
Abstain: 0		Crosswalk to 0175UCMS agrees with the majority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
17
151010X52UPLAGenomic Sequencing Related Tests TARGETED Drug metabolism pharmacogenomics/pharmcogeneticsDrug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 27 gene report, with variant analysis and reported phenotypesCrosswalk to 0175U: 4
Gapfill: 8
Abstain: 0		Crosswalk to 0175UCMS agrees with the minority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
18
1620286UPLAGenomic Sequencing Related Tests TARGETED Drug metabolism pharmacogenomics/pharmcogeneticsCEP72 (centrosomal protein, 72-KDa), NUDT15 (nudix hydrolase 15) and TPMT (thiopurine S-methyltransferase) (eg, drug metabolism) gene analysis, common variants

Gapfill: 12
Abstain: 0		Crosswalk to 0030UCMS disagrees with the Panel Recommendation and instead is recommending a crosswalk. The crosswalked code(s) appear to use similar methods and resource utilization.
19
17670331U
PLAGenomic Sequencing Related Tests WHOLE GENOMEOncology (hematolymphoid neoplasia), optical genome mapping for copy number alterations and gene rearrangements utilizing DNA from blood or bone marrow, report of clinically significant alternations
Crosswalk to 81229: 12
Gapfill: 0
Abstain: 0
GapfillCMS disagrees with the recommendation of the CDLT Panel and recommends to gapfill this code so that the resources used in this code can be better estimated by a Medicare Administrative Contractor (MAC).
20
18880X38UPLAGenomic Sequencing Related Tests WHOLE GENOMERare diseases (constitutional/heritable disorders), whole genome sequence analysis, including small sequence changes, copy number variants, deletions, duplications, mobile element insertions, uniparental disomy (UPD), inversions, aneuploidy, mitochondrial genome sequence analysis with heteroplasmy and large deletions, short tandem repeat (STR) gene expansions, blood or saliva, identification and categorization of genetic variants, each comparator genome (eg, parent)Crosswalk to 0215U: 12
Gapfill: 0
Abstain: 0		Crosswalk to 0215UCMS agrees with the majority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
21
19860X36UPLAGenomic Sequencing Related Tests WHOLE GENOMERare diseases (constitutional/heritable disorders), whole genome sequence analysis, including small sequence changes, copy number variants, deletions, duplications, mobile element insertions, uniparental disomy (UPD), inversions, aneuploidy, mitochondrial genome sequence analysis with heteroplasmy and large deletions, short tandem repeat (STR) gene expansions, fetal sample, identification and categorization of genetic variantsCrosswalk to 0214U: 12
Gapfill: 0
Abstain: 0		Crosswalk to 0214UCMS agrees with the majority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
22
20910X41U
*Code has Advanced Diagnostic Laboratory Test (ADLT) status		PLAGenomic Sequencing Related Tests WHOLE GENOME
Oncology (pan-cancer), analysis of minimal residual disease (MRD) from plasma, with assays personalized to each patient based on prior next-generation sequencing of the patient’s tumor and germline DNA, reported as absence or presence of MRD, with disease-burden correlation, if appropriateGapfill: 12
Abstain: 0
*Code has Advanced Diagnostic Laboratory Test (ADLT) status		Test is ADLT. N/A
23
21220306UPLAGenomic Sequencing Related Tests TARGETED; cf DNAOncology (minimal residual disease [MRD]), next-generation targeted sequencing analysis, cell-free DNA, initial (baseline) assessment to determine a patient-specific panel for future comparisons to evaluate for MRD

(Do not report 0306U in conjunction with 0307U) 		Gapfill: 12
Abstain: 0		GapfillCMS agrees with the majority recommendation of the CDLT Panel to gapfill this code so that the resources used in this code can be better estimated by a Medicare Administrative Contractor (MAC).
24
22230307UPLAGenomic Sequencing Related Tests TARGETED; cf DNAOncology (minimal residual disease [MRD]), next-generation targeted sequencing analysis of a patient-specific panel, cell-free DNA, subsequent assessment with comparison to previously analyzed patient specimens to evaluate for MRD
(Do not report 0307U in conjunction with 0306U)		Gapfill: 12
Abstain: 0		GapfillCMS agrees with the majority recommendation of the CDLT Panel to gapfill this code so that the resources used in this code can be better estimated by a Medicare Administrative Contractor (MAC).
25
23340318UPLAGenomic Sequencing Related Tests TARGETED METHYLATION ANALYSISPediatrics (congenital epigenetic disorders), whole genome methylation analysis by microarray for 50 or more genes, blood
Gapfill: 12
Abstain: 0		GapfillCMS agrees with the majority recommendation of the CDLT Panel to gapfill this code so that the resources used in this code can be better estimated by a Medicare Administrative Contractor (MAC).
26
24570229UReconsideration/ Substantially Revised Genomic Sequencing Related Tests TARGETED METHYLATION ANALYSISBCAT1 (Branched chain amino acid transaminase 1) and IKZF1 (IKAROS family zinc finger 1) (eg, colorectal cancer) promoter methylation analysisCrosswalk to 81327 x 2: 11
Crosswalk to 81327: 1
Gapfill: 0
Abstain: 0		Crosswalk to 81327 x 2CMS agrees with the majority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
27
254081349ReconsiderationGenomic Sequencing Related Tests TARGETED CHROMOSOME
Cytogenomic (genome-wide) analysis for constitutional chromosomal abnormalities; interrogation of genomic regions for copy number and loss-of-heterozygosity variants, low-pass sequencing analysisCrosswalk to 81229 x 2: 1
Crosswalk to 81229: 11
Gapfill: 0
Abstain: 0		Crosswalk to 81229CMS agrees with the majority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
28
26920X42UPLAGenomic Sequencing Related Tests TARGETED CHROMOSOME Fetal aneuploidy DNA sequencing comparative analysis, fetal DNA from products of conception, reported as normal (euploidy), monosomy, trisomy, or partial deletion/duplication, mosaicism, and segmental aneuploidGapfill: 11
Abstain: 1		GapfillCMS agrees with the majority recommendation of the CDLT Panel to gapfill this code so that the resources used in this code can be better estimated by a Medicare Administrative Contractor (MAC).
29
2771814XXNEWGenomic Sequencing Related Tests TARGETEDInherited bone marrow failure syndromes (IBMFS) (eg, Fanconi anemia, dyskeratosis congenita, Diamond-Blackfan anemia, Shwachman-Diamond syndrome, GATA2 deficiency syndrome, congenital amegakaryocytic thrombocytopenia) sequence analysis panel, must include sequencing of at least 30 genes, including BRCA2, BRIP1, DKC1, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, GATA1, GATA2, MPL, NHP2, NOP10, PALB2, RAD51C, RPL11, RPL35A, RPL5, RPS10, RPS19, RPS24, RPS26, RPS7, SBDS, TERT, and TINF2Crosswalk to 81443: 12
Gapfill: 0
Abstain: 0		Crosswalk to 81443CMS agrees with the majority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
30
28850X35UPLAGenomic Sequencing Related Tests TARGETED VARIANTS, REARRANGEMENTS, MICROSATELLITE INSTABILITYOncology (solid organ), targeted genomic sequence analysis, formalin-fixed paraffin-embedded (FFPE) tumor tissue, DNA analysis, 84 or more genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burdenCrosswalk to 0244U: 11
Gapfill: 1		Crosswalk to 81455CMS disagrees with the Panel Recommendation and instead is recommending a crosswalk. The crosswalked code(s) appear to use similar methods and resource utilization.
31
29820276URevisionGenomic Sequencing Related Tests TARGETEDHematology (inherited thrombocytopenia), genomic sequence analysis of 42 genes, blood, buccal swab, or amniotic fluidCrosswalk to 81443: 12
Gapfill: 0
Abstain: 0		Crosswalk to 81443CMS agrees with the majority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
32
30690022UReconsiderationGenomic Sequencing Related Tests TARGETED VARIANTS; DNA and RNATargeted genomic sequence analysis panel, cholangiocarcinoma and non-small cell lung neoplasia, DNA and RNA analysis, 1-23 genes, interrogation for sequence variants and rearrangements, reported as presence/absence of variants and associated therapy(ies) to considerCrosswalk to 0022U: 12
Gapfill: 0
Abstain: 0		Crosswalk to 81445CMS disagrees with the Panel Recommendation and instead is recommending a crosswalk. The crosswalked code(s) appear to use similar methods and resource utilization.
33
3172814X1NEWGenomic Sequencing Related Tests TARGETED VARIANTS, REARRANGEMENTSTargeted genomic sequence analysis panel, solid organ neoplasm, 5-50 genes (eg, ALK, BRAF, CDKN2A, EGFR, ERBB2, KIT, KRAS, NRAS, MET, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation for sequence variants and copy number variants or rearrangements, if performed; RNA analysisCrosswalk to 81445: 12
Gapfill: 0
Abstain: 0		Crosswalk to 81445CMS agrees with the majority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
34
327681445NEWGenomic Sequencing Related Tests TARGETED VARIANTS, REARRANGEMENTSTargeted genomic sequence analysis panel, solid organ neoplasm, 5-50 genes (eg, ALK, BRAF, CDKN2A, EGFR, ERBB2, KIT, KRAS, NRAS, MET, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation for sequence variants and copy number variants or rearrangements, if performed; DNA analysis or combined DNA and RNA analysisCrosswalk to 81445: 12
Gapfill: 0
Abstain: 0		Crosswalk to 81445CMS agrees with the majority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
35
3374814X3NEWGenomic Sequencing Related Tests TARGETED VARIANTS, REARRANGEMENTS, ISOFORM; RNA; EXPRESSIONTargeted genomic sequence analysis panel, solid organ or hematolymphoid neoplasm or disorder, 51 or greater genes (eg, ALK, BRAF, CDKN2A, CEBPA, DNMT3A, EGFR, ERBB2, EZH2, FLT3, IDH1, IDH2, JAK2, KIT, KRAS, MLL, NPM1, NRAS, MET, NOTCH1, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation for sequence variants and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; RNA analysisCrosswalk to 81455: 12
Gapfill: 0
Abstain: 0		Crosswalk to 81455CMS agrees with the majority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
36
34620326U
PLAGenomic Sequencing Related Tests TARGETED VARIANTS, REARRANGEMENTS, MICORSATELLITE INSTABILITYTargeted genomic sequence analysis panel, solid organ neoplasm, cell-free circulating DNA analysis of 83 or more genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden
Crosswalk to 0242U: 12
Gapfill: 0
Abstain: 0		Crosswalk to 81455CMS disagrees with the Panel Recommendation and instead is recommending a crosswalk. The crosswalked code(s) appear to use similar methods and resource utilization.
37
3573814X2NEWGenomic Sequencing Related Tests TARGETED VARIANTS, REARRANGEMENTS, ISOFORM EXPRESSIONTargeted genomic sequence analysis panel, hematolymphoid neoplasm or disorder, 5-50 genes (eg, BRAF, CEBPA, DNMT3A, EZH2, FLT3, IDH1, IDH2, JAK2, KRAS, KIT, MLL, NRAS, NPM1, NOTCH1), interrogation for sequence variants, and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; RNA analysisCrosswalk to 81450: 12
Gapfill: 0
Abstain: 0		Crosswalk to 81450CMS agrees with the majority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
38
36900X40UPLAGenomic Sequencing Related Tests TARGETED; mRNA
Oncology (prostate), mRNA expression profiling of HOXC6 and DLX1, reverse transcription polymerase chain reaction (RT-PCR), first-void urine following digital rectal examination, algorithm reported as probability of high-grade cancerCrosswalk to 0005U: 12
Gapfill: 0
Abstain: 0		Crosswalk to 0005UCMS agrees with the majority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
39
37320316UPLAMicrobiologyBorrelia burgdorferi (Lyme disease), OspA protein evaluation, urine Crosswalk to 87449 + 87015: 12
Gapfill: 0
Abstain: 0
Crosswalk to 87499 + 87015CMS agrees with the majority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
40
3877862XX
8X002		NEWMicrobiologyHepatitis B surface antigen (HBsAg), quantitativeCrosswalk to 86316: 3
Crosswalk to 84702: 8
Gapfill: 1
Abstain: 0		Crosswalk to 84702CMS agrees with the majority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
41
396887913
879X1		NEWMicrobiologyInfectious agent genotype analysis by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), mutation identification in targeted region(s)Crosswalk to 87910: 12
Gapfill: 0
Abstain: 0		Crosswalk to 87910CMS agrees with the majority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
42
407887X68
8X009		NEWMicrobiologyInfectious agent detection by nucleic acid (DNA or RNA); Anaplasma phagocytophilum, amplified probe techniqueCrosswalk to 87476: 12
Gapfill: 0
Abstain: 0		Crosswalk to 87476CMS agrees with the majority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
43
417987X70
8X010		NEWMicrobiologyInfectious agent detection by nucleic acid (DNA or RNA); Babesia microti, amplified probe techniqueCrosswalk to 87476: 12
Gapfill: 0
Abstain: 0		Crosswalk to 87476CMS agrees with the majority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
44
428087X77
8X011		NEWMicrobiologyInfectious agent detection by nucleic acid (DNA or RNA); Borrelia miyamotoi, amplified probe techniqueCrosswalk to 87476: 12
Gapfill: 0
Abstain: 0		Crosswalk to 87476CMS agrees with the majority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
45
438187X99
8X012		NEWMicrobiologyInfectious agent detection by nucleic acid (DNA or RNA); Ehrlichia chaffeensis, amplified probe techniqueCrosswalk to 87476: 12
Gapfill: 0
Abstain: 0		Crosswalk to 87476CMS agrees with the majority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
46
44270311UPLAMicrobiology Infectious disease (bacterial), quantitative antimicrobial susceptibility reported as phenotypic minimum inhibitory concentration (MIC)–based antimicrobial susceptibility for each organism identified

(Do not report 0311U in conjunction with 87076, 87077, 0086U)		Gapfill: 11
Abstain: 1
Crosswalk to 87077CMS disagrees with the Panel Recommendation and instead is recommending a crosswalk. The crosswalked code(s) appear to use similar methods and resource utilization.
47
45170301UPLAMicrobiologyInfectious agent detection by nucleic acid (DNA or RNA), Bartonella henselae and Bartonella quintana, droplet digital PCR (ddPCR);

Crosswalk to 87471: 4
Crosswalk to 87472: 0
Gapfill: 8
Abstain: 0
Crosswalk to 87471CMS agrees with the minority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
48
46180302UPLAMicrobiologyInfectious agent detection by nucleic acid (DNA or RNA), Bartonella henselae and Bartonella quintana, droplet digital PCR (ddPCR); following liquid enrichmentCrosswalk to 87471: 3
Crosswalk to 87472: 0
Gapfill: 8
Abstain: 1
Crosswalk to 87471CMS agrees with the minority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
49
47370321UPLAMicrobiologyInfectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogens, identification of 20 bacterial and fungal organisms and identification of 16 associated antibiotic-resistance genes, multiplex amplified probe technique
Crosswalk to 87633 + 87632: 11
Gapfill: 1
Abstain: 0		Crosswalk to 87633 + 87632CMS agrees with the majority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
50
48590323UPLAMicrobiologyInfectious agent detection by nucleic acid (DNA and RNA), central nervous system pathogen, metagenomic next-generation sequencing, cerebrospinal fluid (CSF), identification of pathogenic bacteria, viruses, parasites or fungi
Crosswalk to 0152U: 8
Gapfill: 3
Abstain: 1
Crosswalk to 0152UCMS disagrees with the Panel Recommendation and instead is recommending a crosswalk. The crosswalked code(s) appear to use similar methods and resource utilization.
51
49660330U
PLAMicrobiology Infectious agent detection by nucleic acid (DNA or RNA), vaginal pathogen panel, identification of 27 organisms, amplified probe technique, vaginal swab

Crosswalk to 87633: 12
Gapfill: 0
Abstain: 0		Crosswalk to 87633 CMS agrees with the majority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
52
501030X54UPLAMicrobiology
Infectious disease (bacterial vaginosis and vaginitis), multiplex amplified probe technique, for detection of bacterial vaginosis–associated bacteria (BVAB-2, Atopobium vaginae, and Megasphera type 1), algorithm reported as detected or not detected and separate detection of Candida species (C. albicans, C. tropicalis, C. parapsilosis, C. dubliniensis), Candida glabrata/Candida krusei, and trichomonas vaginalis, vaginal-fluid specimen, each result reported as detected or not detectedCrosswalk to 87631: 11
Gapfill: 0
Abstain: 1		Crosswalk to 87631 CMS agrees with the majority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
53
511040X55UPLAMicrobiologyInfectious agent detection by nucleic acid (DNA), Chlamydia trachomatis and Neisseria gonorrhoeae, multiplex amplified probe technique, urine, vaginal, pharyngeal, or rectal, each pathogen reported as detected or not detectedCrosswalk to 87491 + 87591: 11
Gapfill: 0
Abstain: 1		Crosswalk to 87491 + 87591CMS agrees with the majority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
54
52190303UPLAHematology and CoagulationHematology, red blood cell (RBC) adhesion to endothelial/subendothelial adhesion molecules, functional assessment, whole blood, with algorithmic analysis and result reported as an RBC adhesion index; hypoxicGapfill: 12
Abstain: 0
GapfillCMS agrees with the majority recommendation of the CDLT Panel to gapfill this code so that the resources used in this code can be better estimated by a Medicare Administrative Contractor (MAC).
55
53200304UPLAHematology and CoagulationHematology, red blood cell (RBC) adhesion to endothelial/subendothelial adhesion molecules, functional assessment, whole blood, with algorithmic analysis and result reported as an RBC adhesion index; normoxicGapfill: 12
Abstain: 0
GapfillCMS agrees with the majority recommendation of the CDLT Panel to gapfill this code so that the resources used in this code can be better estimated by a Medicare Administrative Contractor (MAC).
56
54210305UPLAHematology and CoagulationHematology, red blood cell (RBC) functionality and deformity as a function of shear stress, whole blood, reported as a maximum elongation index
Gapfill: 12
Abstain: 0
GapfillCMS agrees with the majority recommendation of the CDLT Panel to gapfill this code so that the resources used in this code can be better estimated by a Medicare Administrative Contractor (MAC).
57
5510285UPLATests with algorithm in code descriptor to report risk/likelihood/predictive score Oncology, response to radiation, cell-free DNA, quantitative branched chain DNA amplification, plasma, reported as a radiation toxicity score
Crosswalk to 81595: 0
Crosswalk to 0118U: 0
Gapfill: 12
Abstain: 0		GapfillCMS agrees with the majority recommendation of the CDLT Panel to gapfill this code so that the resources used in this code can be better estimated by a Medicare Administrative Contractor (MAC).
58
5630287UPLATests with algorithm in code descriptor to report risk/likelihood/predictive score Oncology (thyroid), DNA and mRNA, next generation sequencing analysis of 112 genes, fine needle aspirate or formalinfixed paraffin-embedded (FFPE) tissue, algorithmic prediction of cancer recurrence, reported as a categorical risk result (low, intermediate, high)

Crosswalk to 0026U: 12 Gapfill: 0 Abstain: 0 Crosswalk to 0026UCMS agrees with the majority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
59
5740288UPLATests with algorithm in code descriptor to report risk/likelihood/predictive score Oncology (lung), mRNA, quantitative PCR analysis of 11 genes (BAG1, BRCA1, CDC6, CDK2AP1, ERBB3, FUT3, IL11, LCK, RND3, SH3BGR, WNT3A) and 3 reference genes (ESD, TBP, YAP1), formalin-fixed paraffin-embedded (FFPE) tumor tissue, algorithmic interpretation reported as a recurrence risk score

Crosswalk to 81522: 12
Gapfill: 0
Abstain: 0
Crosswalk to 81522CMS agrees with the majority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
60
5850289UPLATests with algorithm in code descriptor to report risk/likelihood/predictive score Neurology (Alzheimer disease), mRNA, gene expression profiling by RNA sequencing of 24 genes, whole blood, algorithm reported as predictive risk score
Crosswalk to 0239U: 1
Crosswalk to 0203U: 6
Gapfill: 5
Abstain: 0		Crosswalk to 0203UCMS agrees with the majority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
61
5960290UPLATests with algorithm in code descriptor to report risk/likelihood/predictive score Pain management, mRNA, gene expression profiling by RNA sequencing of 36 genes, whole blood, algorithm reported as predictive risk score
Crosswalk to 0239U: 0
Crosswalk to 0203U: 6
Gapfill: 6
Abstain: 0		Crosswalk to 0203UCMS agrees with the half of the CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
62
6070291UPLATests with algorithm in code descriptor to report risk/likelihood/predictive score Psychiatry (mood disorders), mRNA, gene expression profiling by RNA sequencing of 144 genes, whole blood, algorithm reported as predictive risk score

Crosswalk to 0239U: 0
Crosswalk to 0258U: 2
Gapfill: 10
Abstain: 0		Crosswalk to 0239UCMS disagrees with the Panel Recommendation and instead is recommending a crosswalk. The crosswalked code(s) appear to use similar methods and resource utilization.
63
6180292UPLATests with algorithm in code descriptor to report risk/likelihood/predictive score Psychiatry (stress disorders), mRNA, gene expression profiling by RNA sequencing of 72 genes, whole blood, algorithm reported as predictive risk score
Crosswalk to 0239U: 0
Crosswalk to 0258U: 1
Gapfill: 11
Abstain: 0		Crosswalk to 0239UCMS disagrees with the Panel Recommendation and instead is recommending a crosswalk. The crosswalked code(s) appear to use similar methods and resource utilization.
64
6290293UPLATests with algorithm in code descriptor to report risk/likelihood/predictive score Psychiatry (suicidal ideation), mRNA, gene expression profiling by RNA sequencing of 54 genes, whole blood, algorithm reported as predictive risk score
Crosswalk to 0239U: 0
Crosswalk to 0258U: 1
Gapfill: 11
Abstain: 0

Crosswalk to 0203UCMS disagrees with the Panel Recommendation and instead is recommending a crosswalk. The crosswalked code(s) appear to use similar methods and resource utilization.
65
63100294UPLATests with algorithm in code descriptor to report risk/likelihood/predictive score Longevity and mortality risk, mRNA, gene expression profiling by RNA sequencing of 18 genes, whole blood, algorithm reported as predictive risk score

Crosswalk to 0239U: 0
Crosswwalk to 0175U: 2
Gapfill: 10
Abstain: 0
Crosswalk to 0203UCMS disagrees with the Panel Recommendation and instead is recommending a crosswalk. The crosswalked code(s) appear to use similar methods and resource utilization.
66
64110295UPLATests with algorithm in code descriptor to report risk/likelihood/predictive score Oncology (breast ductal carcinoma in situ), protein expression profiling by immunohistochemistry of 7 proteins (COX2, FOXA1, HER2, Ki-67, p16, PR, SIAH2), with 4 clinicopathologic factors (size, age, margin status, palpability), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a recurrence risk score

Crosswalk to 0045U: 0
Crosswalk to 0067U: 10
Gapfill: 2
Abstain: 0		Crosswalk to 0067UCMS agrees with the majority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
67
65240308UPLATests with algorithm in code descriptor to report risk/likelihood/predictive score Cardiology (coronary artery disease [CAD]), analysis of 3 proteins (high sensitivity [hs] troponin, adiponectin, and kidney injury molecule-1 [KIM-1]), plasma, algorithm reported as a risk score for obstructive CAD

Crosswalk to 0105U: 1
Crosswalk to 81506: 10
Gapfill: 1
Abstain: 0		Crosswalk to 81506CMS agrees with the majority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
68
66650329U
PLAGenomic Sequencing Related Tests TARGETED EXOME TRANSCRIPTOME, VARIANTS, REARRANGEMENTS, MICORSATELLITE INSTABILITYOncology (neoplasia), exome and transcriptome sequence analysis for sequence variants, gene copy number amplifications and deletions, gene rearrangements, microsatellite instability and tumor mutational burden utilizing DNA and RNA from tumor with DNA from normal blood or saliva for subtraction, report of clinically significant mutation(s) with therapy associations
Crosswalk to 0036U: 5
Gapfill: 7
Abstain: 0		GapfillCMS agrees with the majority recommendation of the CDLT Panel to gapfill this code so that the resources used in this code can be better estimated by a Medicare Administrative Contractor (MAC).
69
67250309UPLATests with algorithm in code descriptor to report risk/likelihood/predictive score Cardiology (cardiovascular disease), analysis of 4 proteins (NT-proBNP, osteopontin, tissue inhibitor of metalloproteinase-1 [TIMP-1], and kidney injury molecule-1 [KIM-1]), plasma, algorithm reported as a risk score for major adverse cardiac event

Crosswalk to 0105U: 1
Crosswalk to 81506: 9
Gapfill: 2
Abstain: 0		Crosswalk to 81506CMS agrees with the majority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
70
68260310UPLATests with algorithm in code descriptor to report risk/likelihood/predictive score Pediatrics (vasculitis, Kawasaki disease [KD]), analysis of 3 biomarkers (NTproBNP, C-reactive protein, and T-uptake), plasma, algorithm reported as a risk score for KD
Crosswalk to 0105U: 0
Crosswalk to 81506: 11
Gapfill: 1
Abstain: 0		Crosswalk to 81506CMS agrees with the majority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
71
69630327U
PLATests with algorithm in code descriptor to report risk/likelihood/predictive score Fetal aneuploidy (trisomy 13, 18, and 21), DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy, includes sex reporting, if performed
Crosswalk to 81420: 0
Crosswalk to 81507: 12
Gapfill: 0
Abstain: 0
Crosswalk to 81507CMS agrees with the majority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
72
70330317UPLATests with algorithm in code descriptor to report risk/likelihood/predictive score Oncology (lung cancer), four-probe FISH (3q29, 3p22.1, 10q22.3, 10cen) assay, whole blood, predictive algorithm generated evaluation reported as decreased or increased risk for lung cancer
Crosswalk to 0053U: 1
Gapfill: 11
Abstain: 0
Crosswalk to 0053UCMS agrees with the minority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
73
71350319UPLATests with algorithm in code descriptor to report risk/likelihood/predictive score Nephrology (renal transplant), RNA expression by select transcriptome sequencing, using pretransplant peripheral blood, algorithm reported as a risk score for early acute rejection
Crosswalk to 81542: 0
Gapfill: 12
Abstain: 0		GapfillCMS agrees with the majority recommendation of the CDLT Panel to gapfill this code so that the resources used in this code can be better estimated by a Medicare Administrative Contractor (MAC).
74
72360320UPLATests with algorithm in code descriptor to report risk/likelihood/predictive score Nephrology (renal transplant), RNA expression by select transcriptome sequencing, using posttransplant peripheral blood, algorithm reported as a risk score for acute cellular rejection
Crosswalk to 81542: 0
Gapfill: 12
Abstain: 0		GapfillCMS agrees with the majority recommendation of the CDLT Panel to gapfill this code so that the resources used in this code can be better estimated by a Medicare Administrative Contractor (MAC).
75
73300314UPLATests with algorithm in code descriptor to report risk/likelihood/predictive score Oncology (cutaneous melanoma), mRNA gene expression profiling by RT-PCR of 35 genes (32 content and 3 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical result (ie, benign, intermediate, malignant)
Crosswalk to 81529: 8
Crosswalk to 0090U: 4
Gapfill: 0
Abstain: 0		Crosswalk to 0090UCMS agrees with the minority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
76
74310315UPLATests with algorithm in code descriptor to report risk/likelihood/predictive score Oncology (cutaneous squamous cell carcinoma), mRNA gene expression profiling by RT-PCR of 40 genes (34 content and 6 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical risk result (ie, Class 1, Class 2A, Class 2B)
Crosswalk to 81529: 7
Gapfill: 5
Abstain: 0		Crosswalk to 0090UCMS disagrees with the Panel Recommendation and instead is recommending a crosswalk. The crosswalked code(s) appear to use similar methods and resource utilization.
77
75120296UPLATests with algorithm in code descriptor to report risk/likelihood/predictive score Oncology (oral and/or oropharyngeal cancer), gene expression profiling by RNA sequencing at least 20 molecular features (eg, human and/or microbial mRNA), saliva, algorithm reported as positive or negative for signature associated with malignancy

Crosswalk to 0170U: 8
Gapfill: 4
Abstain: 0		Crosswalk to 0170UCMS agrees with the majority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
78
76580245UReconsiderationTests with algorithm in code descriptor to report risk/likelihood/predictive score
Oncology (thyroid), mutation analysis of 10 genes and 37 RNA fusions and expression of 4 mRNA markers using next-generation sequencing, fine needle aspirate, report includes associated risk of malignancy expressed as a percentage)Crosswalk to 81455: 4
Gapfill: 8
Abstain: 0		GapfillCMS agrees with the majority recommendation of the CDLT Panel to gapfill this code so that the resources used in this code can be better estimated by a Medicare Administrative Contractor (MAC).
79
77290313UPLATests with algorithm in code descriptor to report risk/likelihood/predictive score Oncology (pancreas), DNA and mRNA next-generation sequencing analysis of 74 genes and analysis of CEA (CEACAM5) gene expression, pancreatic cyst fluid, algorithm reported as a categorical result (ie, negative, low probability of neoplasia or positive, high probability of neoplasia)
Crosswalk to 0026U: 12 Gapfill: 0
Abstain: 0		Crosswalk to 0026UCMS agrees with the majority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
80
78600324UPLATests with algorithm in code descriptor to report risk/likelihood/predictive score Oncology (ovarian), spheroid cell culture, 4-drug panel (carboplatin, doxorubicin, gemcitabine, paclitaxel), tumor chemotherapy response prediction for each drug
Crosswalk to 0248U: 7
Gapfill: 4
Abstain: 1		Crosswalk to 81535 + 81536 x 3CMS disagrees with the Panel Recommendation and instead is recommending a crosswalk. The crosswalked code(s) appear to use similar methods and resource utilization.
81
79610325U
PLATests with algorithm in code descriptor to report risk/likelihood/predictive score Oncology (ovarian), spheroid cell culture, poly (ADP-ribose) polymerase (PARP) inhibitors (niraparib, olaparib, rucaparib, velparib), tumor response prediction for each drug
Crosswalk to 0248U: 8
Gapfill: 3
Abstain: 1		Crosswalk to 81535 + 81536 x 3CMS disagrees with the Panel Recommendation and instead is recommending a crosswalk. The crosswalked code(s) appear to use similar methods and resource utilization.
82
80830X33UPLATests with algorithm in code descriptor to report risk/likelihood/predictive score THERAPYOncology (pan-tumor), genetic profiling of 8 DNA-regulatory (epigenetic) markers by quantitative polymerase chain reaction (qPCR), whole blood, reported as a high or low probability of responding to immune checkpoint–inhibitor therapyGapfill: 12
Abstain: 0		GapfillCMS agrees with the majority recommendation of the CDLT Panel to gapfill this code so that the resources used in this code can be better estimated by a Medicare Administrative Contractor (MAC).
83
81840X34UPLATests with algorithm in code descriptor to report risk/likelihood/predictive scoreOncology (liver), surveillance for hepatocellular carcinoma (HCC) in high-risk patients, analysis of methylation patterns on circulating cell-free DNA (cfDNA) plus measurement of serum of AFP/AFP-L3 and oncoprotein des-gamma-carboxy-prothrombin (DCP), algorithm reported as normal or abnormal resultCrosswalk to 81420 + 82107 +83951: 0
Gapfill: 12
Abstain: 0		GapfillCMS agrees with the majority recommendation of the CDLT Panel to gapfill this code so that the resources used in this code can be better estimated by a Medicare Administrative Contractor (MAC).
84
82940X44UPLATests with algorithm in code descriptor to report risk/likelihood/predictive score (darkest highlight)
Oncology (prostate), exosome-based analysis of 442 small noncoding RNAs (sncRNAs) by quantitative reverse transcription polymerase chain reaction (RT-qPCR), urine, reported as molecular evidence of no-, low-, intermediate- or high- risk prostate of cancerCrosswalk to 0005U: 8
Gapfill: 4
Abstain: 0		Crosswalk to 0005UCMS agrees with the majority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
85
83380322UPLATests with algorithm in code descriptor to report risk/likelihood/predictive score/ ChemistryNeurology (autism spectrum disorder [ASD]), quantitative measurements of 14 acyl carnitines and microbiome-derived metabolites, liquid chromatography with tandem mass spectrometry (LC-MS/MS), plasma, results reported as negative or positive for risk of metabolic subtypes associated with ASD
Crosswalk to 0063U: 7
Gapfill: 5
Abstain: 0		Crosswalk to 0063UCMS agrees with the majority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
86
84640328U
PLATests with algorithm in code descriptor to report risk/likelihood/predictive score Drug assay, definitive, 120 or more drugs and metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS), includes specimen validity and algorithmic analysis describing drug or metabolite and presence or absence of risks for a significant patient adverse event, per date of service
Crosswalk to 0143U: 5
Crosswalk to 0150U: 1
Gapfill 6
Abstain: 0		Crosswalk to 0143UCMS agrees with the minority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
87
851020X53UPLATests with algorithm in code descriptor to report risk/likelihood/predictive score
Infectious disease (bacterial or viral), biochemical assays, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), interferon gamma-induced protein-10 (IP-10), and C-reactive protein, serum, algorithm reported as likelihood of bacterial infectionCrosswalk to 81500: 10
Gapfill: 1
Abstain: 1
Crosswalk to 81500CMS agrees with the majority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
88
86930X43UPLATests with algorithm in code descriptor to report risk/likelihood/predictive score ELECTROCHEMILUMINESCENT IMMUNOASSAY (ECLIA) + ALGORITHM
Oncology (pancreatic cancer), multiplex immunoassay of C5, C4, cystatin C, factor B, osteoprotegerin (OPG), gelsolin, IGFBP3, CA125 and multiplex electrochemiluminescent immunoassay (ECLIA) for CA19-9, serum, diagnostic algorithm reported qualitatively as positive, negative, or borderlineCrosswalk to 81503: 10
Crosswalk to 81490: 1
Gapfill: 1
Abstain: 0		Crosswalk to 81503CMS agrees with the majority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
89
87280312UPLAImmunology ELISA
Autoimmune diseases (eg, systemic lupus erythematosus [SLE]), analysis of 8 IgG autoantibodies and 2 cell-bound complement activation products using enzyme-linked immunosorbent immunoassay (ELISA), flow cytometry and indirect immunofluorescence, serum, or plasma and whole blood, individual components reported along with an algorithmic SLE-likelihood assessment

Crosswalk to 0062U: 9
Crosswalk to 0003U: 3
Abstain: 0		Crosswalk to 81490CMS disagrees with the Panel Recommendation and instead is recommending a crosswalk. The crosswalked code(s) appear to use similar methods and resource utilization.
90
884286015
ReconsiderationImmunologyActin (smooth muscle) antibody (ASMA), eachCrosswalk to 86146: 9
Crosswalk to 83516: 2
Gapfill: 1
Abstain: 0		Crosswalk to 86255CMS disagrees with the Panel Recommendation and instead is recommending a crosswalk. The crosswalked code(s) appear to use similar methods and resource utilization.
91
894386036ReconsiderationImmunologyANCA screen, eachCrosswalk to 86146: 10
Crosswalk to 84586: 0
Crosswalk to 86255: 2
Gapfill: 0
Abstain: 0		Crosswalk to 86255CMS agrees with the minority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
92
904486037ReconsiderationImmunologyANCA titerCrosswalk to 86146: 8
Crosswalk to 86256: 4
Gapfill: 0
Abstain: 0		Crosswalk to 86256CMS agrees with the minority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
93
914586051ReconsiderationImmunologyAquaporin-4 (neuromyelitis optica [NMO]) antibody; enzyme-linked immunosorbent immunoassay (ELISA)Crosswalk to 86146: 11
Crosswalk to 83516: 1
Gapfill: 0
Abstain: 0		Crosswalk to 83516CMS agrees with the minority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
94
924686052ReconsiderationImmunologyAquaporin-4 (neuromyelitis optica [NMO]) antibody; cell-based immunofluorescence assay (CBA), eachCrosswalk to 86341: 12
Crosswalk to 86255: 0
Gapfill: 0
Abstain: 0 		Crosswalk to 86255CMS agrees with the minority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
95
934786053ReconsiderationImmunologyAquaporin-4, flow cytometry (ie, fluorescence-activated cell sorting [FACS])Crosswalk to 86367: 12
Crosswalk to 86255: 0
Gapfill: 0
Abstain: 0		Crosswalk to 86357CMS disagrees with the Panel Recommendation and instead is recommending a crosswalk. The crosswalked code(s) appear to use similar methods and resource utilization. A public comment suggested this crosswalk for a different test that also counts cells in a similar way.
96
944886231ReconsiderationImmunologyEndomysial antibodyCrosswalk to 86038 x 2: 5
Crosswalk to 86038: 3
Gapfill: 4
Abstain: 0		Crosswalk to 86038CMS agrees with the minority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.
97
954986258ReconsiderationImmunologyGliadin (deamidated) (DGP) antibodyCrosswalk to 86147: 11
Crosswalk to 83516: 1
Gapfill: 0
Abstain: 0		Crosswalk to 86255CMS disagrees with the Panel Recommendation and instead is recommending a crosswalk. The crosswalked code(s) appear to use similar methods and resource utilization.
98
965086362ReconsiderationImmunologyMOG IgG1, cell-based immunofluorescence assayCrosswalk to 86357: 12
Gapfill: 0
Abstain: 0		Crosswalk to 86255CMS disagrees with the Panel Recommendation and instead is recommending a crosswalk. The crosswalked code(s) appear to use similar methods and resource utilization.
99
975186363ReconsiderationImmunologyMOG IgG1, flow cytometry (ie, fluorescence-activated cell sorting [FACS]Crosswalk to 86367: 12
Crosswalk to 86255: 0
Gapfill: 0
Abstain: 0		Crosswalk to 86357CMS disagrees with the Panel Recommendation and instead is recommending a crosswalk. The crosswalked code(s) appear to use similar methods and resource utilization.
100
985286364ReconsiderationImmunologyTissue transglutaminase, each immunoglobulinCrosswalk 86147: 11
Crosswalk 83516: 1
Gapfill: 0
Abstain: 0		Crosswalk to 83516CMS agrees with the minority CDLT Panel recommendation to crosswalk the code. The crosswalked code(s) appear to use similar methods and resource utilization.